Posted inCardiology news
Targeting NEK7 with an Oral Molecular-Glue Degrader: MRT-8102 Advances an Upstream Inflammasome Strategy for Cardiovascular Inflammation
Preclinical AHA 2025 data show MRT-8102, an oral NEK7-directed molecular glue degrader, selectively degrades NEK7, suppresses NLRP3 inflammasome activation and pyroptosis across species, and reduces multi-cytokine release—supporting Phase 1 evaluation in cardiovascular inflammation.